Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About SCPH Interactive Breakdown Better Bets vs. SCPH Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

scPharmaceuticals (SCPH)

Market Price (10/31/2025): $5.67 | Market Cap: $304.6 Mil
Sector: Health Care | Industry: Biotechnology

scPharmaceuticals (SCPH)

Market Price (10/31/2025): $5.67
Market Cap: $304.6 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 108%		  Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -67 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -133%
1   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -132%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -132%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35%
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 108%
1 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -67 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -133%
2 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -132%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -132%
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35%

Market Valuation & Key Metrics

SCPHS&P 500
REVENUE GROWTHVERY GOOD
Rev LTM ($ Bil)0.0
Rev Chg Q99.2%6.5%
Rev Chg LTM107.8%5.4%
Rev Chg 3Y Avg328.8%5.3%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)-0.1
CFO LTM ($ Bil)-0.1
Net Inc LTM ($ Bil)-0.1
Op Mgn LTM-133.2%18.7%
CFO/Rev LTM-131.8%20.3%
Net Inc Mgn-183.5%12.7%
VALUATIONHIGH
P/S6.13.2
P/CFO-4.615.3
P/FCF-4.620.3
P/E-3.323.6
STABILITYVERY GOOD
Debt/Equity0.170.21
Cash/Assets0.510.07

SCPH Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
null

null
null

null
null

null

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
SCPH Return-7%-5%43%-13%-44%-100%�
Peers Return-15%-9%-6%-3%-3%-16%-43%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
SCPH Win Rate58%50%58%50%33%56% 
Peers Win Rate18%15%23%31%22%51% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
SCPH Max Drawdown-9%-27%-22%-34%-50%-43% 
Peers Max Drawdown-20%-13%-14%-15%-30%-27% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique KeyEventSCPHS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-60.0%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven149.8%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-52.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven112.0%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven856 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-85.7%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven598.4%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days

Compare to VRTX, APM, BBOT, GDTC, HIND


In The Past

scPharmaceuticals's stock fell -60.0% during the 2022 Inflation Shock from a high on 5/12/2023. A -60.0% loss requires a 149.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About scPharmaceuticals (SCPH)

Better Bets than scPharmaceuticals (SCPH)

 SCPHBetter Performance than SCPH
MetricValueIndustry (Biotechnology)
Rev Chg LTM107.8%MDGL (3422.0%), CYTK (2635.7%), ARWR (2816.2%), KRYS (116.1%), NAMS (762.1%)
Op Mgn LTM-133.2%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (26.7%)
CFO/Rev LTM-131.8%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM-131.8%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield-30.1%ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)
 SCPHBetter Performance than SCPH
MetricValueAll Other Sectors
Rev Chg LTM107.8%NBIS (542.6%), CRDO (175.8%), ALAB (163.8%), EXE (169.1%), CG (133.3%)
Op Mgn LTM-133.2%NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM-131.8%NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM-131.8%NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield-30.1%NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)
 Best Bets In Health Care Sector
 SCPHRPRX HALO CPRX BMY LNTH PBH BIIB PFE EW ILMN
What You Pay           
P/E-3.315.314.112.315.414.014.013.612.811.812.4
P/EBIT-3.68.111.010.59.39.69.010.110.329.210.3
What You Get           
Rev Chg Q99.2%7.7%40.8%19.4%2.8%-4.1%-6.6%2.8%10.3%11.9%-4.8%
Rev Chg LTM107.8%3.0%35.0%28.5%1.3%5.7%0.6%4.8%13.5%9.1%-3.3%
Rev Chg 3Y Avg�0.8%35.5%49.9%1.0%34.3%0.8%-0.9%-12.4%3.0%-3.0%
FCF/Rev 3Y Avg-592.7%113.4%43.4%38.9%29.0%26.1%21.6%17.0%13.8%11.9%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopic
0DASHBOARDS 
1How Low Can scPharmaceuticals Stock Really Go?Return

Trade Ideas

Select past ideas related to SCPH. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.2%4.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.3%16.3%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		3.8%3.8%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.0%14.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.5%13.5%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.2%4.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.3%16.3%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		3.8%3.8%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.0%14.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.5%13.5%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines279.1%161.2%
2INBXInhibrx Biosciences131.0%409.8%
3PUMPProPetro99.6%16.2%
4DYNDyne Therapeutics88.4%-0.0%
5VICRVicor85.4%89.2%
6CELCCelcuity74.6%503.2%
7GLUEMonte Rosa Therapeutics73.5%87.5%
8NVTSNavitas Semiconductor72.1%251.8%
9LUMNLumen Technologies70.3%94.7%
10BALYBallys63.4%4.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-62.9%5106.3%
2LRNStride-53.8%-35.8%
3FMCFMC-51.0%-66.6%
4FIFiserv-48.3%-68.3%
5NFENew Fortress Energy-43.6%-91.9%
6VGVenture Global-41.7% 
7OGNOrganon-40.2%-55.0%
8VRNSVaronis Systems-39.5%-21.2%
9ITGRInteger-38.5%-52.2%
10LENZLENZ Therapeutics-37.9%5.5%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for scPharmaceuticals

Financials

SCPHVRTXAPMBBOTGDTCHINDMedian
NamescPharma.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Price-419.891.4712.002.155.585.58
Mkt Cap0.3107.8----54.0
Rev LTM5011,419-0--50
Op Inc LTM-67-199--93---93
FCF LTM-663,500--60---60
FCF 3Y Avg-611,984----962
CFO LTM-663,846--60---60
CFO 3Y Avg-612,324----1,131

Growth & Margins

SCPHVRTXAPMBBOTGDTCHINDMedian
NamescPharma.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Rev Chg LTM107.8%10.5%----59.1%
Rev Chg 3Y Avg-11.0%----11.0%
Rev Chg Q99.2%12.1%----55.6%
QoQ Delta Rev Chg LTM19.0%2.9%----10.9%
Op Mgn LTM-133.2%-1.7%-----67.5%
Op Mgn 3Y Avg-531.6%26.5%-----252.5%
QoQ Delta Op Mgn LTM25.7%2.0%----13.8%
CFO/Rev LTM-131.8%33.7%-----49.1%
CFO/Rev 3Y Avg-592.5%22.5%-----285.0%
FCF/Rev LTM-131.8%30.6%-----50.6%
FCF/Rev 3Y Avg-592.7%19.2%-----286.7%

Valuation

SCPHVRTXAPMBBOTGDTCHINDMedian
NamescPharma.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Cap0.3107.8----54.0
P/S6.19.4----7.8
P/EBIT-3.624.5----10.5
P/E-3.329.6----13.2
P/CFO-4.628.0----11.7
Total Yield-30.1%3.4%-----13.4%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-28.1%2.1%-----13.0%
D/E0.20.0----0.1
Net D/E0.0-0.0-----0.0

Returns

SCPHVRTXAPMBBOTGDTCHINDMedian
NamescPharma.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
1M Rtn-7.2%-27.2%3.6%8.0%7.7%7.2%
3M Rtn--8.1%-5.2%-14.4%--5.2%
6M Rtn--15.8%59.8%--6.5%--6.5%
12M Rtn--11.6%5.0%--3.4%--3.4%
3Y Rtn-34.6%-76.8%----21.1%
1M Excs Rtn-2.2%-34.2%-1.9%5.3%-0.2%-0.2%
3M Excs Rtn--18.5%-2.1%-8.1%--2.1%
6M Excs Rtn--37.6%38.0%--28.3%--28.3%
12M Excs Rtn--29.0%-17.8%--33.2%--29.0%
3Y Excs Rtn--41.0%-151.9%----96.5%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/14/20253/19/202511/13/20248/14/20245/14/20243/13/202411/8/20238/10/20235/10/20233/22/202311/9/2022
Key Financials Quarterly            
Total Revenue1612121086642200
Ebitda-17-18-17-33-15-12-12-14-12-9-7-10
Operating Income-14-18-16-18-14-16-15-15-14-12-10-10
Net Income-18-20-19-35-17-14-14-16-14-11-9-10
EPS-0.34-0.37-0.35-0.75-0.44-0.36-0.35-0.41-0.36-0.30-0.30-0.37
Key Financials TTM            
Total Revenue TTM5042363024181474200
Ebitda TTM-85-84-77-72-52-49-46-42-38-35-33-32
Operating Income TTM-67-67-65-64-60-60-55-50-45-40-36-33
Net Income TTM-92-91-85-80-61-58-55-50-45-40-37-35
Growth Rates Quarterly            
Total Revenue Growth99.2%92.6%99.3%164.1%391.7%195.8%------
EBITDA Growth-11.1%-53.0%-48.2%-145.0%-23.8%-30.8%-63.4%-40.4%-31.9%-28.6%-8.9%-67.5%
Operating Income Growth0.9%-12.0%-7.1%-22.3%-5.0%-37.2%-60.6%-48.5%-45.9%-59.6%-41.4%-69.3%
Net Income Growth-5.5%-39.9%-36.4%-124.5%-20.7%-25.9%-49.4%-53.8%-46.0%-45.0%-26.4%-55.1%
Margins Quarterly            
EBITDA Margin-103.2%-155.7%-142.8%-331.7%-185.1%-195.9%-192.2%-357.6%-734.7%-443.2%--
Operating Income Margin-89.1%-151.1%-134.5%-181.0%-179.2%-259.8%-250.3%-390.9%-839.2%-560.1%--
Net Income Margin-112.4%-168.0%-155.1%-350.1%-212.2%-231.2%-226.6%-411.9%-864.1%-543.4%--
Cash & Debt            
Total Cash415876913958769010311611845
Total Debt525253524141404038383711
Net Debt / (Cash)12-5-23-393-18-36-50-65-78-81-35
Cash Flows Quarterly            
FCF from Operations-16-17-15-17-20-18-15-13-14-16-12-8
Cash Flows TTM            
FCF from Operations TTM-66-70-71-71-67-60-59-56-51-44-35-30
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-14.5%-18.9%-18.3%-21.4%-17.8%-21.0%-21.6%-22.3%-22.0%-19.7%-17.4%-18.7%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-16.9%-17.7%-18.2%-18.8%-18.6%-19.7%-19.6%-18.6%-17.9%-17.2%-16.6%-15.6%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Product revenues, net140   
Total140   


Assets by Segment
$ Mil20242023202220212020
Single Segment  7910977
Total  7910977


Price Behavior

SCPH Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.320.741.310.840.911.09
Up Beta0.662.920.150.130.410.68
Down Beta-0.01-1.12-0.150.850.980.89
Up Capture51%82%344%382%169%230%
Bmk +ve Days13233574144420
Stock +ve Days12223568123353
Down Capture-0%-4%109%139%121%108%
Bmk -ve Days8192952107330
Stock -ve Days6172553121385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/2025-7.6%-1.2%11.4%
3/19/2025-1.0%-1.0%-15.5%
11/13/2024-14.1%-14.1%-18.4%
8/12/20242.3%19.9%15.5%
3/13/2024-2.6%2.6%-9.4%
11/8/2023-8.7%-2.1%12.8%
8/10/20231.3%-4.9%-2.1%
3/22/202325.1%30.8%44.4%
...
SUMMARY STATS   
# Positive11107
# Negative8912
Median Positive3.6%17.5%15.5%
Median Negative-6.9%-4.9%-8.5%
Max Positive40.7%32.0%69.6%
Max Negative-14.1%-19.0%-36.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025514202510-Q 3/31/2025
12312024319202510-K 12/31/2024
93020241113202410-Q 9/30/2024
6302024814202410-Q 6/30/2024
3312024514202410-Q 3/31/2024
12312023313202410-K 12/31/2023
93020231108202310-Q 9/30/2023
6302023810202310-Q 6/30/2023
3312023510202310-Q 3/31/2023
12312022322202310-K 12/31/2022
93020221109202210-Q 9/30/2022
6302022809202210-Q 6/30/2022
3312022516202210-Q 3/31/2022
12312021322202210-K 12/31/2021
93020211109202110-Q 9/30/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.